A vendor name for a blend of four peptides: BPC-157, TB-500, GHK-Cu and KPV. Health Canada named such a blend among unauthorized products it seized in a notice of 24 December 2025.

KPV Peptide: Evidence, Risks and Legal Status (2026)

Quick answers

What is it?: A lab-made chain of three amino acids: lysine, proline and valine¹². It copies the tail end of a natural hormone that affects inflammation and skin pigment¹. Sellers offer it for gut and skin inflammation¹.
Does it work?: Not shown in people. FDA found no clinical study and no human exposure data for KPV by any route¹. In mice it reduced gut inflammation in two colitis models³⁴. Animal results do not prove human benefit.
Is it safe?: Unknown. FDA found no human safety data and no animal toxicity studies¹. Its adverse event database held no reports through 3 December 2025, but reporting is voluntary¹. Injected peptides can trigger unwanted immune reactions¹.
Is it legal?: Not approved, and US pharmacies may not make it¹⁵. In July 2026, FDA’s advisers voted 8 to 6, with one abstention, to allow it; FDA had not acted by 7 October 2026⁶⁷. Likely banned in sport⁸⁹.
What is in the vials?: Most tested samples failed. Of 17 Finnrick tests of gray-market KPV from March to September 2026, 2 passed, 13 failed its purity-and-dose standard and 2 were incomplete¹⁰. Sellers label vials ‘for research use only’¹¹.

What it is

KPV is a tripeptide: a chain of three amino acids, lysine (K), proline (P) and valine (V), written H-Lys-Pro-Val-OH¹². It matches the last three amino acids of alpha-MSH (alpha-melanocyte-stimulating hormone), a natural hormone that drives skin pigment and damps down inflammation, so it is also written alpha-MSH(11-13)¹². The fragment does not appear to work the way the parent hormone does. In laboratory work it could not displace radiolabeled alpha-MSH from melanocortin receptors, and it failed to raise cyclic AMP in macrophages¹². It still reduced inflammation in mice whose MC1 receptor does not work. The authors concluded that KPV is unlikely to act through melanocortin receptors at all¹². It also lacks alpha-MSH’s pigment-inducing activity¹³. The leading proposal is that a transporter called PepT1 carries KPV into cells. PepT1 moves small peptides, and gut lining cells switch it on during inflammation³. Inside the cell, KPV blocks NF-kappaB and MAP kinase signaling, two switches that turn on inflammatory genes³. FDA’s 2026 review of KPV concluded that its molecular targets remain unknown¹.

The anti-inflammatory activity of alpha-MSH’s tail was mapped in the 1980s. A 1984 study gave the tripeptide to rabbits made feverish and found that it lowered fever, though less strongly than the whole hormone¹⁴. A 1989 mouse study reported that graded doses of the same fragment reduced ear swelling¹⁵. FDA says KPV is a common name, not an official drug name. It has no name from the United States Adopted Names Council, the International Nonproprietary Name system or IUPAC¹⁶. FDA adds that it has met multiple salts and derivatives, including different active molecules, sold under that one name¹¹⁶. Wells Pharmacy Network nominated KPV for FDA’s list of bulk substances that pharmacies may use. The nominated products were a 0.1% cream and gel, for wound healing and inflammatory conditions¹¹⁷. The nomination was later withdrawn, and FDA evaluated the free base and the acetate salt on its own initiative¹. We could not verify who first made KPV as a product, or when¹.

Benefits: what the research shows

We found no published human study of KPV. FDA’s review states that the nomination did not include, and FDA did not identify, any clinical studies or human exposure data for KPV by any route of administration, and that it found no case reports of KPV use in humans¹. A ClinicalTrials.gov search on 5 October 2026 returned no registered KPV trial¹⁸. The human material in the published work is all laboratory based: cultured human gut lining cells and T cells³, blood from patients stimulated with bacterial toxin in a dish¹⁹, and cadaver skin²⁰. The animal work is mostly short mouse and rabbit inflammation models, and the results are generally positive. In two mouse colitis models, KPV given in drinking water reduced gut inflammation, and it roughly halved an inflammation enzyme marker in one of them³. A second group reported earlier recovery, weight regain and less inflammation in two further colitis models, including in mice with a non-functioning MC1 receptor⁴. KPV also reduced white cell influx in crystal-induced peritonitis in mice¹², prevented colitis-associated tumors in normal mice but not in mice lacking the PepT1 transporter²¹, and lowered fever in rabbits¹⁴. Rabbit eye drops re-covered all eight of eight scraped corneas within 60 hours, while no placebo-treated cornea had healed²². Later work relies on delivery systems rather than plain KPV: hyaluronic-acid nanoparticles in a hydrogel given by mouth²³, and a 2026 modified version that reached the colon better and worked at a 20-fold lower dose²⁴. One mouse study of brain injury reported a smaller lesion after a single dose²⁵. Against this, a skin study found that KPV barely crosses human cadaver skin without a device to push it through²⁰. FDA judged the whole package insufficient. The nominator submitted eight non-clinical articles, three of which FDA set aside as studies of other molecules¹. FDA found no studies of effectiveness in humans, no pharmacokinetic data and no toxicity studies, and noted that approved treatments exist for conditions such as psoriasis and eczema¹.

Key human studies

No completed human studies were found.

Doses studied

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

In human studies

None. Neither FDA nor our searches found a human study of KPV, so we know of no dose tested in people by any route, including the 0.1% topical cream and gel nominated to FDA and the injected, oral and nasal products sold online¹¹⁸.

In animal studies

As reported in the papers, in animals only. Mice with colitis: KPV at 100 micromolar in drinking water³. Mice with crystal-induced peritonitis: systemic KPV before the irritant¹². Rabbits with fever: 0.5 to 2.0 mg into the brain and 2 to 200 mg by peripheral routes¹⁴. Rabbits with scraped corneas: drops of 1, 5 or 10 mg/ml, 30 microlitres, two drops four times a day for 4 days²². Mice with brain injury: 1 mg/kg into the abdomen 30 minutes after the injury²⁵. These are animal doses. They are not human doses, and we do not convert them.

What users report Anecdotal · not validated · not a recommendation

One community protocol page lists 200 to 500 micrograms a day³⁶, and a second community site gives the same daily range³⁷. FDA found no human study of KPV, so none supports these figures¹.

Routes: Topical cream and gel (the form nominated to FDA; no human data found)
Injection under the skin (a common gray-market route; no human data found)
By mouth, as capsules (no human data found; mouse studies used drinking water or nanoparticles)
Nasal spray (no human data found)
Eye drops (one rabbit study)

Every dose studied for KPV, with sources →

Legal status

United States: KPV is not approved by FDA for any use. Neither the free base nor the acetate salt has a USP or NF monograph, and neither is a component of an FDA-approved drug¹¹⁶. No KPV trial was registered on ClinicalTrials.gov as of 5 October 2026¹⁸. FDA’s review also found that no outsourcing facility (a 503B compounder, which reports the drugs it makes) had reported compounding KPV from 2017 to June 2025¹.
US pharmacies: Under section 503A, pharmacies may compound only with bulk ingredients that have a USP or NF monograph, are part of an FDA-approved drug or are on FDA’s 503A bulks list. Under an interim policy, FDA also does not intend to act against compounding with substances in its ‘Category 1’⁵. KPV fits none of these routes: it is on no category list on FDA’s 503A lists updated 14 May 2026⁵. It was in Category 2 (substances that may pose significant safety risks) until the nominator withdrew its nomination. FDA now lists it as ‘nominated but withdrawn’ and says it lacks important information about any safety issues KPV raises, including whether it would cause harm if given to humans (page current 22 April 2026)²⁶. FDA announced the removal of twelve peptides, KPV among them, from Category 2 in April 2026; the law firm that reported it stressed that removal does not make those substances eligible for compounding²⁹. FDA evaluated the free base and the acetate salt for wound healing and inflammatory conditions such as psoriasis and eczema, in the nominated 0.1% cream and gel¹¹⁷. In a review dated 12 May 2026 it proposed not adding either form, citing poor characterization, no evidence of effectiveness in humans, no human safety data, no toxicity studies and the availability of approved treatments¹. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8 for, 6 against, with 1 abstention, in favor of each form anyway, against FDA’s own review team, according to two law-firm accounts⁶³⁰. The vote is advisory, and FDA has said any final decision will come through notice-and-comment rulemaking⁶. As of 7 October 2026, FDA’s meeting page (content current 6 August 2026) listed no minutes or transcript⁷, and the 503A category lists were still dated 14 May 2026⁵. A Federal Register search for FDA documents mentioning the committee, published since 1 April 2026, found the July meeting notice but no proposed rule³¹.
Other countries: Canada: Health Canada listed KPV among the peptides found in unauthorized products it has seized, in a public advisory of 9 April 2026. It said peptides are generally regulated as prescription drugs in Canada and that labeling a product ‘research use only’ does not make it legal to sell³². In a seizure announced 24 December 2025, it named a four-peptide blend containing KPV sold through a Vancouver business³³. UK: The Guardian reported on 4 April 2026 that the MHRA, the UK medicines regulator, would investigate peptide clinics over health claims³⁴; the UK legal status of KPV itself was not verified. EU and Japan: FDA found no KPV product authorized by the European Medicines Agency and no monograph in the European Pharmacopoeia 11.8 or the 18th edition of the Japanese Pharmacopoeia¹. Australia: KPV is not named in the Poisons Standard in force from 1 October 2026²⁸; how Australian law otherwise treats it was not verified.
Sport: KPV is not named on WADA’s 2026 Prohibited List, which is in force now, or on the 2027 List, which takes effect 1 January 2027⁸⁹. Class S0 bans at all times ‘any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use’⁸. FDA found no KPV product approved in the United States, Canada, the European Union or Japan¹, so in our reading KPV falls under S0. That is our inference, not a WADA ruling. WADA’s explanatory note on the 2027 List, which adds peptides as examples in S0, warns that a peptide not named on the List ‘may still be prohibited and may be harmful to health’²⁷. A 2026 review in a sports medicine journal lists KPV among the peptides promoted in sport and bodybuilding³⁵.

KPV in the legal tracker →

Quality and the gray market

What testing finds

Independent testing is recent and mostly bad. Finnrick, an independent testing service, publishes third-party laboratory results for gray-market peptides. As of 5 October 2026 its KPV page listed 17 tests from 7 vendors, the first on 29 March 2026 and the latest on 10 September 2026¹⁰. Of those, 2 passed, 13 failed and 2 were incomplete, under its default standard of at least 99.5% purity and content within 35% of the label¹⁰³⁸. Finnrick sources samples from vendors and sends them to outside laboratories, and it also offers free testing of samples mailed in by US users, so its results describe the products it tested, not a random sample of the market³⁸. FDA found the manufacturing information no better. No certificate of analysis was provided for the free base, and the certificates FDA found in the public domain report purity only, with no impurity limits or results, nothing on the peptide’s tendency to clump together (aggregation) and no microbial testing¹. The certificate submitted for the acetate salt reported total impurities of 0.9% against a 2.0% limit, and the largest single impurity at 0.24% against a 1.0% limit¹. It gave no information on what those impurities are, no aggregation data, no microbial testing and no description of how the peptide was made¹. FDA concluded that both forms are ‘not well-characterized’, noting the naming problem and that the free base dissolves in water only up to 0.7 mg/mL¹¹⁶.

How it is sold

KPV is sold online as freeze-dried powder in vials labeled for research use only, and through telemedicine and clinics as injections, capsules, topicals and nasal sprays¹¹¹. FDA’s review found websites promoting single-ingredient KPV for inflammatory conditions, wound healing, skin health, immune support, nerve protection, gut health, antimicrobial effects and reducing tumor growth¹. The same pages offered it for mast cell activation syndrome, histamine intolerance, recovery from COVID-19, Lyme disease, mold toxicity and pain syndromes¹. Much of the market is blends. One widely sold four-peptide blend combines KPV with BPC-157, TB-500 and GHK-Cu¹¹³³, and FDA found clinic pages marketing a ‘regenerative combo’ of KPV with BPC-157, TB-500, AOD9604 and follistatin-344 for muscle, joint and cartilage repair¹. Demand is real but far below BPC-157’s. ‘kpv peptide’ and ‘klow peptide’ were both among the rising US Google searches for ‘bpc 157’ in the 12 months to 29 September 2026³⁹, and Finnrick logged 17 KPV tests between March and September 2026¹⁰. On one vendor’s popularity-sorted catalog on 5 October 2026, the four-peptide blend ranked fourth and single-ingredient KPV sixteenth out of 41 products; the same site states that its products are for research use only and not for human consumption¹¹.

Side effects and risks

Unknown human safety. FDA found no human exposure data for KPV by any route, and no animal studies of acute toxicity, repeat-dose toxicity, genotoxicity, reproductive or developmental toxicity, or cancer risk¹.
Immune reactions and clumping. FDA says peptide products can provoke unwanted immune responses, and that it could not assess KPV’s tendency to clump together because the available certificates of analysis contain no aggregation data¹.
You may not be buying what you think. ‘KPV’ is a common name, not an official drug name, and FDA says multiple salts and derivatives, including different active molecules, are marketed under it¹¹⁶.
Product quality. Of 17 Finnrick tests of gray-market KPV between March and September 2026, 13 failed and 2 were incomplete¹⁰.
Missing reports. FDA’s adverse event database held no KPV reports through 3 December 2025, and its food and supplement complaint system had none from 2004 to the same date¹. Reporting is voluntary, and FDA notes that compounders under section 503A generally do not report adverse events to it, so an absence of reports does not mean an absence of harm¹.
The products do not match the data. The one skin study found that KPV barely crosses human skin without a device to drive it through, which undercuts topical use²⁰. Nothing published supports the injected, oral or nasal products that dominate the market¹.
Anti-doping. KPV is not named on WADA’s Lists, but by our reading it falls under class S0, which is banned at all times⁸⁹. WADA warns that peptides not named on the List ‘may still be prohibited’²⁷.
Legal. US pharmacies have no lawful route under section 503A to compound KPV⁵, and Health Canada has seized unauthorized products containing it³²³³.

Documented harms

9 Apr 2026Health Canada warned that peptides bought online can seriously harm health and listed KPV among the substances in unauthorized products it seized. The advisory reports no case of harm from KPV itself³².

Questions people ask

Is KPV FDA approved?

No. No FDA-approved product contains KPV, and US pharmacies have no lawful route to compound it¹⁵. FDA’s compounding advisers voted 8 to 6, with 1 abstention, to allow it on 23 July 2026, but the vote is advisory and FDA had posted no minutes or rule as of 7 October 2026⁶⁷.

Has KPV been tested in people?

No. FDA’s 2026 review found no clinical study, no human exposure data by any route and no published case reports¹, and no KPV trial was registered on ClinicalTrials.gov as of 5 October 2026¹⁸.

Does KPV help with colitis or Crohn’s disease?

Not shown in people. KPV reduced inflammation in mouse colitis models and in cultured human gut cells³⁴, but FDA found no study that gave it to people¹, and we found no registered KPV trial¹⁸.

Is KPV the same as alpha-MSH?

No. KPV is the last three amino acids of alpha-MSH¹. Laboratory work suggests it does not act through the melanocortin receptors the parent hormone uses¹², and it lacks the hormone’s pigment-inducing effect¹³.

What is ‘Klow’?

A vendor name for a blend of four peptides: BPC-157, TB-500, GHK-Cu and KPV¹¹³³. Health Canada named such a blend among unauthorized products it seized in a notice of 24 December 2025³³.

Is KPV banned in sport?

It is not named on WADA’s 2026 or 2027 Prohibited Lists, but in our reading it falls under class S0, which bans substances with no government approval for human use at all times⁸⁹. WADA warns that unnamed peptides ‘may still be prohibited’²⁷.

What is still unknown

Who first produced KPV as a product, and when. Community pages credit an industry team in 2002, which we could not verify.
Whether KPV exists in the body as a free peptide. FDA’s review says it is naturally produced as a fragment of alpha-MSH, but the sentence cites a clinic blog post, so we do not state it as fact.
Whether KPV has an official substance identifier. FDA’s review lists no UNII code for either form, while FDA’s Global Substance Registration System carries a UNII for L-lysyl-L-prolyl-L-valine; we could not confirm when that record was created.
What FDA will do after the 23 July 2026 advisory vote. As of 7 October 2026 there were no minutes, no proposed rule and no change to the category lists.
Whether KPV reaches the gut lining or the bloodstream from any product sold. No human or animal pharmacokinetic study exists.
Whether the 1989 mouse ear-swelling study used KPV or its acetylated form. The published abstract says alpha-MSH(11-13); FDA’s review classes that paper as a study of N-acetylated KPV and sets it aside.
Whether Finnrick’s 17 tests reflect the wider market. Its KPV page gives 7 vendors in the header and a larger vendor table that includes vendors with no tests.
Whether Australia’s melanocyte-stimulating hormone entry could capture KPV as a derivative. The Poisons Standard says a listing covers derivatives after a balanced consideration of factors, and we could not locate the parent entry text.
The legal status of KPV in the UK, the EU and Australia beyond the checks reported above.

Sources

1FDA Evaluation of KPV-Related Bulk Drug Substances (KPV (Free Base) and KPV Acetate), Pharmacy Compounding Advisory Committee briefing document U.S. Food and Drug Administration, 12 May 2026. fda.gov
2KPV (Lys-Pro-Val), CID 125672 PubChem, U.S. National Library of Medicine, accessed 5 Oct 2026. pubchem.ncbi.nlm.nih.gov
3PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation Gastroenterology, Jan 2008. pubmed.ncbi.nlm.nih.gov
4Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease Inflammatory Bowel Diseases, Mar 2008. pubmed.ncbi.nlm.nih.gov
5Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
6PEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A List FDA Law Blog (Hyman, Phelps & McNamara), 24 Jul 2026. thefdalawblog.com
7July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, 6 Aug 2026. fda.gov
8World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
9World Anti-Doping Code International Standard: Prohibited List 2027 World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
10KPV: safety testing results and vendor ratings Finnrick, 10 Sep 2026. finnrick.com
11Ascension Peptides shop page sorted by popularity Ascension Peptides (vendor), accessed 5 Oct 2026. ascensionpeptides.com (seller page, deliberately not linked)
12Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides Journal of Pharmacology and Experimental Therapeutics, Aug 2003. pubmed.ncbi.nlm.nih.gov
13Are melanocortin peptides future therapeutics for cutaneous wound healing? Experimental Dermatology, Mar 2019. pubmed.ncbi.nlm.nih.gov
14Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit Peptides, 1984. pubmed.ncbi.nlm.nih.gov
15Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH FASEB Journal, Sep 1989. pubmed.ncbi.nlm.nih.gov
16FDA presentations, July 23, 2026, Pharmacy Compounding Advisory Committee meeting U.S. Food and Drug Administration, 23 Jul 2026. fda.gov
17Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments (91 FR 20465) Federal Register (U.S. Food and Drug Administration), 16 Apr 2026. federalregister.gov
18ClinicalTrials.gov search for ‘KPV’ (no registered study) ClinicalTrials.gov, accessed 5 Oct 2026. clinicaltrials.gov
19Melanocortin peptides inhibit production of proinflammatory cytokines in blood of HIV-infected patients Peptides, 1998. pubmed.ncbi.nlm.nih.gov
20Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin Journal of Pharmaceutical Sciences, Jul 2017. pubmed.ncbi.nlm.nih.gov
21Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model Cellular and Molecular Gastroenterology and Hepatology, May 2016. pubmed.ncbi.nlm.nih.gov
22Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide Experimental Eye Research, Dec 2006. pubmed.ncbi.nlm.nih.gov
23Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis Molecular Therapy, 5 Jul 2017. pubmed.ncbi.nlm.nih.gov
24Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers Science Advances, 16 Jan 2026. pubmed.ncbi.nlm.nih.gov
25Single administration of tripeptide alpha-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain injury in mice PLoS One, 2013. pubmed.ncbi.nlm.nih.gov
26Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration, 22 Apr 2026. fda.gov
27Summary of Major Modifications and Explanatory Notes: 2027 Prohibited List World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
28Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327) Federal Register of Legislation, Australian Government, 28 Sep 2026. legislation.gov.au
29FDA to Remove 12 Popular Peptides from the Category 2 ‘Do Not Compound’ List Frier Levitt, 16 Apr 2026. frierlevitt.com
30Bulk-list bound? PCAC backs majority of peptides in two-day public meeting McDermott Will & Schulte, 27 Jul 2026. mcdermottlaw.com
31Federal Register search: FDA documents mentioning “Pharmacy Compounding Advisory Committee” published since 1 April 2026 Federal Register, accessed 8 Oct 2026. federalregister.gov
32Think twice before injecting peptides bought online: unauthorized products can seriously harm you (RA-81874) Health Canada, 9 Apr 2026. recalls-rappels.canada.ca
33Unauthorized health products sold online and seized at Rize Fitness may pose serious health risks (RA-81403) Health Canada, 24 Dec 2025. recalls-rappels.canada.ca
34Medicines watchdog to investigate UK peptide clinics over health claims The Guardian, 4 Apr 2026. theguardian.com
35A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review The Journal of Sports Medicine and Physical Fitness, Jul 2026. pubmed.ncbi.nlm.nih.gov
36KPV 10 mg vial: dosage protocol PeptideDosages.com, 20 Sep 2026. peptidedosages.com
37KPV (Alpha-MSH Fragment) Dosage, Safety & Stacks Peptide Initiative, 10 Aug 2026. peptideinitiative.com
38Methodology Finnrick, accessed 5 Oct 2026. finnrick.com
39Google Trends: rising related queries for ‘bpc 157’, United States, 12 months to 29 September 2026 Google Trends, accessed 30 Sep 2026. trends.google.com

Not medical advice. This page reports what studies and regulators say; it does not recommend using any product. How we grade evidence · Report an error.